UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
Kinase Fusion Gene:CHRM3_FLT3 |
Kinase Fusion Protein Summary |
Kinase Fusion gene summary |
Kinase Fusion partner gene information | Kinase Fusion gene name: CHRM3_FLT3 | KinaseFusionDB ID: KFG1284 | FusionGDB2.0 ID: KFG1284 | Hgene | Tgene | Gene symbol | CHRM3 | FLT3 | Gene ID | 1131 | 2322 | |
Gene name | cholinergic receptor muscarinic 3 | fms related receptor tyrosine kinase 3 | ||||||||||
Synonyms | EGBRS|HM3|PBS|m3AChR | CD135|FLK-2|FLK2|STK1 | ||||||||||
Cytomap | 1q43 | 13q12.2 | ||||||||||
Type of gene | protein-coding | protein-coding | ||||||||||
Description | muscarinic acetylcholine receptor M3acetylcholine receptor, muscarinic 3m3 muscarinic receptor | receptor-type tyrosine-protein kinase FLT3CD135 antigenFL cytokine receptorfetal liver kinase 2fms related tyrosine kinase 3fms-like tyrosine kinase 3growth factor receptor tyrosine kinase type IIIstem cell tyrosine kinase 1 | ||||||||||
Modification date | 20240411 | 20240411 | ||||||||||
UniProtAcc | P20309 | P36888 | ||||||||||
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000255380, ENST00000468573, | ENST00000241453, ENST00000380982, ENST00000469894, ENST00000537084, | |||||||||
Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: CHRM3 [Title/Abstract] AND FLT3 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | CHRM3(239693491)-FLT3(28520991), # samples:1 |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | CHRM3 | GO:0019722 | calcium-mediated signaling | 17478539 |
Hgene | CHRM3 | GO:0032412 | regulation of monoatomic ion transmembrane transporter activity | 17478539 |
Hgene | CHRM3 | GO:0095500 | acetylcholine receptor signaling pathway | 17478539 |
Tgene | FLT3 | GO:0030097 | hemopoiesis | 7507245 |
Kinase Fusion gene breakpoints across CHRM3 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Kinase Fusion gene breakpoints across FLT3 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
Kinase Fusion gene information. |
Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
ChiTaRS5.0 | EI789568 | CHRM3 | chr1 | 239693491 | FLT3 | chr13 | 28520991 |
Top |
Kinase Fusion ORF Analysis |
Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:239693491/:28520991) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
CHRM3 | FLT3 |
FUNCTION: The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover. {ECO:0000269|PubMed:7565628}. | FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways. {ECO:0000269|PubMed:10080542, ECO:0000269|PubMed:11090077, ECO:0000269|PubMed:14504097, ECO:0000269|PubMed:16266983, ECO:0000269|PubMed:16627759, ECO:0000269|PubMed:18490735, ECO:0000269|PubMed:20111072, ECO:0000269|PubMed:21067588, ECO:0000269|PubMed:21262971, ECO:0000269|PubMed:21516120, ECO:0000269|PubMed:7507245}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
- Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of CHRM3_FLT3 |
Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
FLT3 | P36888 | human | FLT3 | P36888 | Y955 | ADAEEAMyQNVDGRV | |
FLT3 | P36888 | human | FLT3 | P36888 | Y726 | kEHNFSFyPtFQSHP | PK_Tyr_Ser-Thr |
FLT3 | P36888 | human | FLT3 | P36888 | Y591 | SSDNEyFyVDFREyE | |
FLT3 | P36888 | human | SIRT3 | Q9NTG7 | Y226 | KGLLLRLyTQNIDGL | |
FLT3 | P36888 | human | IDH1 | O75874 | Y391 | PNVQRsDyLNTFEFM | Iso_dh |
FLT3 | P36888 | human | IDH2 | P48735 | Y107 | sALATQkysVAVkCA | Iso_dh |
FLT3 | P36888 | human | FLT3 | P36888 | Y969 | VSECPHtyQNrrPFS | |
FLT3 | P36888 | human | PTPN11 | Q06124 | Y62 | KIQNtGDyyDLyGGE | SH2 |
FLT3 | P36888 | human | FLT3 | P36888 | Y842 | DIMSDsNyVVRGNAR | PK_Tyr_Ser-Thr |
FLT3 | P36888 | human | FLT3 | P36888 | Y599 | VDFREyEyDLkWEFP | |
FLT3 | P36888 | human | FLT3 | P36888 | Y589 | TGSSDNEyFyVDFRE | |
FLT3 | P36888 | human | PDHA1 | P08559 | Y301 | MsDPGVsyRtREEIQ | E1_dh |
FLT3 | P36888 | human | PDK1 | Q15118 | Y243 | ARRLCDLyyINSPEL |
Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
Enriched GO biological processes of the phosphorylation target genes of the kinase |
Kinase | GOID | GO term | P.adjust |
FLT3 | ID | Description | 0.00e+00 |
FLT3 | GO:0006099 | tricarboxylic acid cycle | 6.25e-05 |
FLT3 | GO:0009060 | aerobic respiration | 7.24e-05 |
FLT3 | GO:0045333 | cellular respiration | 1.12e-04 |
FLT3 | GO:0015980 | energy derivation by oxidation of organic compounds | 2.62e-04 |
FLT3 | GO:0019216 | regulation of lipid metabolic process | 2.62e-04 |
FLT3 | GO:0006086 | acetyl-CoA biosynthetic process from pyruvate | 3.97e-04 |
FLT3 | GO:0006163 | purine nucleotide metabolic process | 5.57e-04 |
FLT3 | GO:0072350 | tricarboxylic acid metabolic process | 5.57e-04 |
FLT3 | GO:0006103 | 2-oxoglutarate metabolic process | 5.57e-04 |
FLT3 | GO:0072521 | purine-containing compound metabolic process | 5.57e-04 |
FLT3 | GO:0006085 | acetyl-CoA biosynthetic process | 6.02e-04 |
FLT3 | GO:0006084 | acetyl-CoA metabolic process | 1.90e-03 |
FLT3 | GO:0006739 | NADP metabolic process | 3.10e-03 |
FLT3 | GO:0035384 | thioester biosynthetic process | 3.10e-03 |
FLT3 | GO:0071616 | acyl-CoA biosynthetic process | 3.10e-03 |
FLT3 | GO:0033866 | nucleoside bisphosphate biosynthetic process | 3.95e-03 |
FLT3 | GO:0034030 | ribonucleoside bisphosphate biosynthetic process | 3.95e-03 |
FLT3 | GO:0034033 | purine nucleoside bisphosphate biosynthetic process | 3.95e-03 |
FLT3 | GO:0006081 | cellular aldehyde metabolic process | 5.45e-03 |
FLT3 | GO:0019362 | pyridine nucleotide metabolic process | 6.28e-03 |
FLT3 | GO:0046496 | nicotinamide nucleotide metabolic process | 6.28e-03 |
FLT3 | GO:0072524 | pyridine-containing compound metabolic process | 6.94e-03 |
FLT3 | GO:0043648 | dicarboxylic acid metabolic process | 7.79e-03 |
FLT3 | GO:0006637 | acyl-CoA metabolic process | 7.79e-03 |
FLT3 | GO:0035383 | thioester metabolic process | 7.79e-03 |
FLT3 | GO:0006090 | pyruvate metabolic process | 1.13e-02 |
FLT3 | GO:0033865 | nucleoside bisphosphate metabolic process | 1.14e-02 |
FLT3 | GO:0033875 | ribonucleoside bisphosphate metabolic process | 1.14e-02 |
FLT3 | GO:0034032 | purine nucleoside bisphosphate metabolic process | 1.14e-02 |
FLT3 | GO:0046887 | positive regulation of hormone secretion | 1.39e-02 |
FLT3 | GO:0045834 | positive regulation of lipid metabolic process | 1.43e-02 |
FLT3 | GO:1902652 | secondary alcohol metabolic process | 1.48e-02 |
FLT3 | GO:0044272 | sulfur compound biosynthetic process | 1.65e-02 |
FLT3 | GO:0050796 | regulation of insulin secretion | 1.68e-02 |
FLT3 | GO:0050731 | positive regulation of peptidyl-tyrosine phosphorylation | 1.69e-02 |
FLT3 | GO:0046890 | regulation of lipid biosynthetic process | 2.03e-02 |
FLT3 | GO:0006006 | glucose metabolic process | 2.03e-02 |
FLT3 | GO:0090276 | regulation of peptide hormone secretion | 2.03e-02 |
FLT3 | GO:0002791 | regulation of peptide secretion | 2.03e-02 |
FLT3 | GO:0030073 | insulin secretion | 2.03e-02 |
FLT3 | GO:0090087 | regulation of peptide transport | 2.03e-02 |
FLT3 | GO:0009152 | purine ribonucleotide biosynthetic process | 2.25e-02 |
FLT3 | GO:0009260 | ribonucleotide biosynthetic process | 2.49e-02 |
FLT3 | GO:0050730 | regulation of peptidyl-tyrosine phosphorylation | 2.49e-02 |
FLT3 | GO:0019318 | hexose metabolic process | 2.49e-02 |
FLT3 | GO:0046390 | ribose phosphate biosynthetic process | 2.49e-02 |
FLT3 | GO:0030072 | peptide hormone secretion | 2.56e-02 |
FLT3 | GO:0002790 | peptide secretion | 2.59e-02 |
FLT3 | GO:0046883 | regulation of hormone secretion | 2.59e-02 |
Top |
Related Drugs to CHRM3_FLT3 |
Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Distribution of the number of studies mentioning CHRM3-FLT3 and kinase inhibitors the PubMed Abstract (04-01-2024) |
Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to CHRM3_FLT3 |
Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
MeSH ID | MeSH term |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
Clinical Trials from clinicaltrials.gov (06-17-2024) |
Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |